Global Angioplasty Balloons Market Analysis

The Global Angioplasty Balloons Market size stood at around xx Bn in 2023 and is projected to reach US $xx Bn by 2033, exhibiting a CAGR of xx% during the forecast period.

The Global Angioplasty Balloons Market Executive Summary

Angioplasty balloons are medical devices that are utilized in angioplasty, which is a process of opening up blocked or narrowed arteries. The balloon is positioned on the catheter and placed through the blood vessel. Once in place, the balloon is inflated, which forces plaque against the arterial wall and opens up the artery to enhance blood flow.

The global angioplasty balloon market is expanding due to increase in cardiovascular diseases, innovation, and increased population of geriatrics. Critical product categories include plain and drug-coated balloons, and the major markets are North America, Europe, and APAC, rapidly growing. The problems are cost and potential legal issues. There is an increased emphasis on innovation and strategic partnerships among top companies. The market outlook is promising, growth is expected owing to improvements in technology and uses in the developing world.    

Global Angioplasty Balloons Market Dynamics

Market Growth Drivers

Growth of the angioplasty balloons market is attributed to the increasing rates of cardiovascular diseases, including coronary artery disease, which requires angioplasty. The trend of moving toward less invasive procedures such as balloon angioplasty has also been driving the entry due to their advantages such as low recovery time. Innovations like drug-eluting and scoring balloons are improving procedure efficiency and minimizing restenosis threat. Furthermore, there is an increasing prevalence of the geriatric population that has a higher risk of developing cardiovascular diseases, and the revenue policies of North America region are encouraging in this regard. 

Opportunity

The angioplasty balloons market has future opportunities in the extension of technology related to drug-eluting and bioresorbable balloons in combination with enhanced imaging systems. Another important trend is the shift towards less invasive treatments and the growth of the healthcare sector in developing countries. Thus, the improved public consciousness and better development of key associations will bring more advancement in innovation and the global marketplace.

Market Restraints

Some of the challenges faced in the angioplasty balloons market are steep procedure costs that make it difficult to afford the product and possible complications like bleeding and heart attack that can discourage the use of the balloons. It can also reduce adoption due to the absence of reimbursement policies, as well as the confined and regulated avenues that digital interventions need to pass through before being approved. However, there are several issues that may slow down the growth of market, including a lack of qualified staff and a tendency to turn to non-conventional approaches. 

Competitive Landscape for Angioplasty Balloons Market in Global

Key Players

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic PLC
• B. Braun Melsungen AG
• Biotronik SE & Co. KG
• Terumo Corporation

Recent Developments

March 2024, Boston Scientific Corporation today announced it has received USFDA approval for the AGENT™ Drug-Coated Balloon, which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.

April 2024, Abbott announced that the USFDA has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.

January 2024, Summa Therapeutics, LLC announced that the company’s Finesse Injectable balloon catheter platform was used in first-in-human injectable angioplasty procedures for patients with below-the-knee (BTK) peripheral artery disease (PAD).

Mergers and Acquisitions

November 2023, OrbusNeich Medical Group Holdings Limited, a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today announced the acquisition of 100% interest in Eucatech AG, a German company principally engaged in the development, manufacture, and sale of minimally invasive cardiovascular and endovascular projects, for EUR2,400,000.

October 2023, Cordis acquires drug-eluting balloon maker MedAlliance for up to $1.135B.

November 2022, Johnson & Johnson announced a definitive agreement for the acquisition of Abiomed, a leader in heart support and recovery technologies, with an upfront payment of USD 380 per share, which equates to USD 16.6 billion.

Healthcare Policies and Regulatory Landscape for Angioplasty Balloons Market in Global

Policy changes and Reimbursement scenario

Market factors that drive market growth include approval of new policies that enhance the utilization of healthcare services, and regulatory approval of new devices such as drug-coated balloons. The focus on using non-invasive strategies corresponds to the positive aspects linked to angioplasty operations. Insured clients especially in North American region increases adoption of solution while insurance reimbursement policies that may be invariable helps increase the market. Other government initiatives for restricting the prices of healthcare services and enhancing access also contribute to the market.